Canada Markets closed

Know Labs, Inc. (KNWN)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.3400-0.1500 (-10.07%)
At close: 03:55PM EST
Sign in to post a message.
  • m
    marcge81
    UNBELIEVABLE NEWS:

    Know Labs Launches Subsidiary, AI Mind Inc., Generates $4.2M in NFT Revenue to Fund Continued Non-Invasive Glucose Monitoring Device Development
    December 16, 2021 09:00 AM Eastern Standard Time
    SEATTLE--(BUSINESS WIRE)--Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that a new subsidiary created to work with the company’s Artificial Intelligence (AI) Deep Learning Platform has generated initial revenue of approximately $4.2 million from Non-Fungible Token (NFT) sales. This revenue will be used to fund ongoing progress toward development of AI technologies for Know Labs’ non-invasive glucose monitoring devices KnowU™ and UBand™.

    “The ability to generate substantial revenue from a subsidiary created to monetize our trade secret AI algorithms is significant, because it potentially provides a new source of funding for our work toward developing what we believe will be the first medical-grade non-invasive glucose monitoring device”

    Tweet this
    The new subsidiary, AI Mind Inc. (AIM), is focused on identifying opportunities to utilize the company’s artificial intelligence, machine learning and proprietary algorithms, which enable the Know Labs Bio-RFIDTM platform to identify and measure blood glucose levels accurately and non-invasively. Know Labs believes it is among the first public companies to generate NFT revenues from AI algorithms.

    The company’s AI engine has the ability to process large amounts of data to identify properties or trends, while recognizing patterns – an essential functionality for Know Labs’ non-invasive blood glucose monitoring devices. While refining the company’s algorithms and enhancing the AI engine, Know Labs CEO Phil Bosua and the company’s engineering team understood the AI engine can be used to recognize complex patterns as well as to create patterns in the form of digital images and text-based solutions.

    The Know Labs team, recognizing the dynamic and growing market for NFTs, in which digital assets are bought and sold on online exchanges, began to develop NFTs in the form of digital art by working with the company’s AI engine. The first 100 NFTs created by the AIM engineering and creative team sold quickly on the NFT exchange, OpenSea. The team created additional batches of NFTs, which also were sold to NFT investors and collectors. Examples of the AI-generated NFTs can be seen here (Explosion of Color) here (Singularity) and here (Light and Dark).

    “We were stunned to discover that the AI engine we have developed can, in addition to identifying molecules non-invasively, also create unique, digital patterns from our test data,” Bosua said. “Our AI engine enables our devices to capture highly accurate blood glucose readings with our Bio-RFID sensors. Now, that same AI engine has begun to generate millions in revenue for our company, which will be used to help fund our vision and achieve our goals. AI is going to be intrinsic to all industries moving forward. We now understand how big the societal impact of AI will be, it will be even bigger than the internet.”

    To date, the Know Labs AIM subsidiary has sold more than 1,000 NFTs and has generated revenue in excess of 1,000 Ethereum, which converted to approximately $4.2 million. The company believes additional revenue may be generated from NFT sales during the first fiscal quarter, with proceeds used to fund the development of Know Labs’ AI technologies powering its non-invasive glucose monitoring devices. Revenue from NFT sales will be reported in the company’s first quarter 10Q, to be filed in February 2022.

    “The ability to generate substantial revenue from a subsidiary created to monetize our trade secret AI algorithms is significant, because it potentially provides a new source of funding for our work toward developing what we believe will be the first medical-grade non-invasive glucose monitoring device,” said Ron Erickson, Know Labs Board Chairman. “Our team remains focused on bringing non-invasive diagnostic devices to market. We will soon kick-off a 200-participant internal clinical trial to refine our AI algorithms and further validate our technology’s accuracy. As we move toward the FDA approval process for our glucose monitoring devices, we’ll continue to seize opportunities to create incremental value for our shareholders, including through our new subsidiary.”

    Know Labs’ technologies rely on a broad variety of patents and data analytics capabilities and the company intends to continue to expand its IP portfolio through a combination of patent filings and development of new inventions. For more information on Know Labs, visit www.knowlabs.co.
  • t
    tim00mike
    Know Labs Non-Invasive Glucose Monitoring Tech - DiabetesMine D-Data Exchange Fall 2021

    https://www.youtube.com/watch?v=kOkbIk6A30k
    Know Labs Non-Invasive Glucose Monitoring Tech - DiabetesMine D-Data Exchange Fall 2021
    www.youtube.com
  • M
    MyN
    Patience. patience. Agree things are slow. Next up is human testing which I am sure they are working on and will share once they get all of the protocols approved.

    Also we need to note the tech they've invented from scratch has other applications so I am thinking that this may provide another revenue source.
  • A
    Anonymous
    selling what? I think the only hope this 'company' has is selling its theoretical IP. Have you seen an alpha product, or a product in a state that can be evaluated in a real-world study? i haven't seen that they made product to any scale, not to mention regulatory filings, FDA testing, peer reviews, nothing. The test numbers they've shown look completely unimpressive to me and procedures don't show any practical real-life scenario (sit completely still in a chair for hours). They should move on to another product to sense in the body, like alcohol. Maybe that's easier than glucose and there's probably a market there. Even the testing would be more fun! I can't stop raving about the great graphics guy or girl. Those are some classy looking shiny conceptual black boxes and a really cool purple glow sensor and i really like the number font they use. that's nice.
  • A
    Ashleigh Palmer
    What do you expect when their CEO looks like Garth from Wayne’s World.
  • F
    Flóki
    Now they are into Crypto? What is the next scam?
  • m
    marcge81
    KNWN: according to their 10K they have enough cash to fund operations for the next 3 years.
  • t
    tim00mike
    Know Labs - Revolutionizing Non-Invasive Medical Diagnostics

    https://www.youtube.com/watch?v=HU7Ee2bLfAs
    Know Labs - Revolutionizing Non-Invasive Medical Diagnostics
    www.youtube.com
  • m
    marcge81
    Know Labs Announces Successful Results from Pre-Clinical Study Validating Bio-RFID™ Platform Technology

    KNWN
    -1.87%
    Wed, June 9, 2021, 9:00 AM·4 min read

    KNWN
    -1.87%

    Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced successful results from an independent pre-clinical study validating the company’s Bio-RFID™ platform technology.

    Know Labs is developing a novel medical device using the Bio-RFID technology that it expects will be the world’s first non-invasive continuous glucose monitor, making finger sticks and micro-needle monitoring devices obsolete and changing care for the world’s 1.5 billion people with diabetes or pre-diabetes. The successful test of the Bio-RFID technology is an important step toward submission of a diagnostic medical device for FDA approval.

    The purpose of the independent pre-clinical research was to confirm that Know Labs’ Bio-RFID technology is able to precisely and non-invasively measure and identify a variety of analytes in vitro by detecting their unique radio frequency spectral responses.

    - ADVERTISEMENT -

    "In the past, we’ve rarely spoken publicly about our test results," said Phil Bosua, Know Labs CEO. "Our energy has been on our research priorities here in the lab. But now we would like to share what we know is a significant milestone – independent verification from a respected research institution that our Bio-RFID technology works."

    The next phase of testing for the Bio-RFID technology will involve clinical human studies measuring blood glucose non-invasively in the body. Data collected from these studies will be included in materials presented to the FDA in a pre-submission meeting. Subsequent clinical trials will be conducted and submitted in the company’s application to the FDA. Know Labs will provide updates on its regulatory strategy and timeline in the coming months.

    The report detailing the results will be submitted for publication in a peer reviewed journal. Upon publication, the report will be made available.

    About Know Labs, Inc.

    Know Labs, Inc. is a public company whose shares trade under the stock symbol "KNWN." The Company’s technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The Company refers to its technology as Bio-RFID. The Bio-RFID technology can be integrated into a variety of wearable, mobile or bench-top form factors. This patented and patent pending technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The first application of our Bio-RFID technology will be in a product marketed as a glucose monitor. It will provide the user with real time information on their blood glucose levels. This product will require US Food and Drug Administration approval prior to its introduction to the market.

    Safe Harbor Statement

    This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words "may," "will," "could," "should," "would," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," "likely," "forecast," "probable," "potential," and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2020, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company u
  • N
    Nollie
    I am very interested in KnowLabs and doing some due diligence I came across this company that is making a similar product https://www.diamontech.de/home is somebody able to explain the differences between the 2 companies? Advantages/Disadvantages... thank you
    DiaMonTech :: Non-Invasive Glucose Measurement
    www.diamontech.de
  • O
    Observer
    This stock will be huge just huge. Not many know what they are really developing but I do as I am an early investor met the company people watched it closely. Extraordinary technological development which could change medical monitoring on many levels. Trust me. Good luck
  • L
    L
    ADDITIONAL IP ANNOUNCED TODAY: Know Labs announced it has been granted 3 new patents that support its medical diagnostic focus while also signaling the potential for non-medical applications. These new patents expand Know Labs’ intellectual property portfolio in radio frequency and microwave spectroscopy, further improving its technological position as it readies to launch non-invasive diagnostic devices.

    https://www.businesswire.com/news/home/20210727005341/en/%C2%A0Three-New-Patents-for-Know-Labs-Expand-IP-Portfolio-and-Signal-Further-Applications-for-Bio-RFID%E2%84%A2
    Advancing the development of its proprietary Bio-RFIDTM platform technology while continuing to deliver against its IP strategy, Know Labs, Inc. (OTCQ
    Advancing the development of its proprietary Bio-RFIDTM platform technology while continuing to deliver against its IP strategy, Know Labs, Inc. (OTCQ
    www.businesswire.com
  • C
    Charlie
    "We are building a breakthrough platform technology that will revolutionize medical diagnostics, beginning with what we believe will be the world’s first non-invasive glucose monitoring device," said Phil Bosua, Know Labs CEO and Bio-RFID inventor. "This patent is critical because without the ability to control the timing of the frequency capture, accurate non-invasive measurements using radio frequency on the human body are not possible. We’ve been granted 22 patents to date and have 35 more pending. Our advances will lead to breakthroughs in diagnostics and potentially disease prevention, so we are pursuing and delivering on a disciplined intellectual property strategy to protect our innovative technology and its value."

    U.S. Patent No. 11,033,208 was issued by the United States Patent and Trademark Office and is titled "Fixed Operation Time Frequency Sweeps for an Analyte Sensor." The patent relates to how operation of the Know Labs Bio-RFID sensor technology is controlled. The sensing routines conducted by the sensor to non-invasively detect an analyte in the body are conducted substantially identically to one another, which means results are obtained under as close to identical conditions as possible. This allows for a more accurate comparison between the results of each sensing routine, increasing the precision and accuracy of the Know Labs Bio-RFID sensor technology in non-invasively measuring and identifying a variety of analytes, including glucose.
  • F
    Fuckov
    Tokyo Company Unveils World's First Wearable Glucose MonitorThe wearable provides 24/7 non-invasive needleless monitoring of blood glucose levels. 

    The new wearable uses the company's patented spectrum technology to accurately measure glucose in a person's bloodstream through the skin without having to use a needle.Using the technology, diabetic patients will be able to replace the daily routine of using a needle for measurements with simply strapping on a wristwatch-like wearable device.Eliminating the pain of daily needle use for diabetic patients Quantum Operation is showcasing its new technology at this year's CES alongside a similar oxygen saturation measuring system sensor (SpO2) wearable device.
  • M
    Marshawn
    Has anyone come across a potential valuation of the patents awarded to Know Labs for their bio RFID technology platform? Looking at the market value of only Dexcom, which is a market leader for only one single application in medical diagnostics...one could make a pretty bullish case for the market value of their IP.
  • A
    Ali G
    Looking at the "prototype," even if I assume that it is "real," it looks like it is a long ways off from becoming a real product. I don't see how the share price takes off until a real product appears in the marketplace, ahead of the competition.
  • O
    Observer
    Extraordinary upside potential. If you all only knew
  • F
    Fuckov
    "Through internal preliminary testing, Particle, Inc. has confirmed the bulb’s efficacy in disinfecting common germs such as E. coli and Staphylococcus. A world renowned, CDC-regulated biosafety level-4 laboratory is currently testing the Particle bulb’s ability to deactivate SARS-CoV-2, the virus that causes COVID-19."
  • A
    Anonymous
    few questions I couldn't find answers to on their website:

    1. no mention of the word "calibrate". does this product work as an absolute number for blood sugar or relative from a starting point, i.e. do you need to calibrate it with a finger stick (how often)?
    2. the accuracy of the G5 has been eclipsed by the newer G6 with G7 just about to be released; why is there a comparison (today) with, almost a generation and a half, old technology?
    3. it looks like the tests were done on a very stationary person, not moving (at. all.). What is product performance with some arm movement, or even normal activity (like typing) or exertion?
    4. some data on how product works on different arms/people? there's one guy in the video.
    5. i have to doubt "as or better accuracy as the G5": I'm under the assumption normal sugar levels do change smoothly as represented by the underlying G5 curve they show, yet KNWN points jumped above and below. I would expect "more accurate" would at least be as smooth and also be compared to an "actual" or reference number, like a glucose meter. I can't see an accurate number for either in the video.

    The concept is cool and the fact they had a working proof of concept is encouraging, but the fact the test subject didn't move a millimeter during the demo video is most suspect to me.